Scientists are actively investigating a potential metabolic protocol involving the concurrent usage of Dulaglutide, a dual GIP/GLP-1 receptor agonist; Mirikizumab, an experimental triple GIP/GLP-1/GCG receptor https://biopeptidestore.com/